Sana Biotechnology Inc (NAS:SANA)
$ 6.68 -0.24 (-3.47%) Market Cap: 1.48 Bil Enterprise Value: 1.33 Bil PE Ratio: 0 PB Ratio: 3.93 GF Score: 39/100

Sana Biotechnology Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 07:00PM GMT
Release Date Price: $25.12 (+0.36%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. I'm Salveen Richter Biotechnology Analyst at Goldman Sachs. Thanks for joining us. We're really pleased to have the Sana team here with us, of which we have Steve Harr, President and CEO Nate Hardy, CFO; and Nicky Keith, VP of Finance.

With that, I'm going to turn it over to Steve to make a couple of opening comments.

Steven D. Harr
Sana Biotechnology, Inc. - President, CEO & Director

Thank you, Salveen. And thank you for hosting us, and thank you to everybody who's listening for joining.

And before we begin, I presume everybody knows, we'll be making forward-looking statements, and we spend a whole bunch of time on our risk factors internally. So please do peruse at your leisure.

So Sana was founded under the belief that one of, if not the most important transformation that will occur in medicine over the next 10 to 20 years, is the ability to modulate genes in use cells as medicine. So we call engineered cells. And our goal is nothing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot